Background <p>Immune checkpoint inhibitor therapy (ICI) with nivolumab+ipilimumab is a first-line (1L) standard for metastatic clear cell renal cell carcinoma (ccRCC), yet outcomes remain heterogeneous. Increasing evidence suggests that host factors influence the tumor microenvironment and response to ICI. Although higher body mass index (BMI) has been associated with improved outcomes in several malignancies, BMI is an imprecise surrogate for…
Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma
Journal for ImmunoTherapy of Cancer | | Grewal, K., Moura Nascimento Santos, M. J., Chauhan, P. K., Yu, K., Tannir, N. M., Mukhida, S. S., Venkatesh, N., Shah, A. Y., Zurita, A. J., Johns, A. C., Campbell, M. T., Goswami, S., Gao, J., Jonasch, E., McQuade, J. L., Alhalabi, O., Msaouel, P., Hahn, A. W.
Topics: colorectal-cancer, kidney-cancer, cervical-cancer, immunotherapy, new-technology
Read the full article at Journal for ImmunoTherapy of Cancer